Noqdirna (oral lyophilisate desmopressin) launched in UK for nocturia due to idiopathic nocturnal polyuria- Ferring Pharma

Ferring Pharmaceuticals has announced the launch of Noqdirna (oral lyophilisate desmopressin) - the only licensed treatment for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults including the over 65s - following approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

The approval of Noqdirna is based on two Phase III studies (CS40 and CS41), with CS40 investigating the efficacy and safety of 25 �g in adult women and CS41 investigating the efficacy and safety of 50 �g in adult men. Both trials demonstrated that the treatment significantly reduced the average number of night-time urinations, compared with the placebo groups. Noqdirna was shown to nearly double the probability of patients achieving the primary endpoint of the studies - listed as a reduction of night-time voids by 33%. Noqdirna was also shown to reduce nocturnal urine volume in men and women by more than 200 ml, and increase time to first void in people with nocturia, allowing people to have an average undisturbed sleep period of approximately 4.5 hours. This extended undisturbed sleep is important due to the early hours of sleep making up the majority of the night's deep sleep - interruption of which is associated with a range of health issues.